Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACcomplisH China: A Phase 2, Multicenter, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With Achondroplasia

Next Previous
Trial Profile

ACcomplisH China: A Phase 2, Multicenter, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With Achondroplasia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Navepegritide (Primary)
  • Indications Achondroplasia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ACcomplisH China
  • Sponsors Ascendis Pharma; VISEN Pharmaceuticals

Most Recent Events

  • 08 Oct 2025 According to an Ascendis Pharma media release, the company announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon CNP as a treatment for children with achondroplasia. The MAA is based on data from three randomized, double-blind, placebo-controlled clinical trials and up to three years of open-label extension data, including results from the pivotal ApproaCH Trial.
  • 07 Jan 2024 Status changed from active, no longer recruiting to completed. According to Ascendis Pharma Media Release.
  • 16 Nov 2023 Primary endpoint (Annualized height velocity (centimeters/year) at 52 weeks) has been met as per results published in the VISEN Pharmaceuticals media relase.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top